Preliminary Programme

Friday, 10 November 2023

8:00 – 08:05 Welcome and Introduction
Alan Wayne, MD; Children's Hospital Los Angeles/University of Southern California
Michael Bishop, MD; University of Chicago
Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
Nicolaus Kroger, MD; University Hospital Hamburg

08:05 – 08:15 Message from the ASTCT and EBMT President’s
Miguel Perales, MD; Memorial Sloan Kettering Cancer Center
Anna Sureda, MD; Institut Català d’Oncologia-Hospital Duran i Reynals

08:15 – 09:00 Keynote: Immunometabolic control of immunity and the effects of fever
Jeffrey Rathmell, PhD; Vanderbilt University

09:00 – 10:30 Session I.A: Immune Reconstitution
Chairs:
Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center, US
Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center, US

Title: NK-like T cells: broad immunity and potential for cell therapy
Speaker: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center

Title: Harnessing mechanisms of tissue regeneration to boost T cell reconstitution after HCT
Speaker: Jarrod Dudakov, PhD; Fred Hutchinson Cancer Center

Session I.B: Microbiome
Chairs:
Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center, US
Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center, US

Title: Microbiome, HCT, and Immunotherapy
Speaker: Jonathan Peled, MD, PhD; Memorial Sloan Kettering Cancer Center

Title: Microbial metabolites rescue antibiotic-associated neutropenia
Speaker: Katherine King, MD, PhD; Baylor College of Medicine

10:30 – 11:00 Break

11:00 – 11:45 Session II: Mechanism of Relapse – Allo
Chairs:
Leslie Kean, MD, PhD; Dana-Farber Cancer Institute/Boston’s Children Hospital, US
Luca Vago, MD, PhD, San Raffaele Scientific Institute, IT

Title: Leukemia Immune Escape and Relapse after Allogeneic HCT: From Biology to Personalized Medicine (And Back)
Speaker: Luca Vago, MD, PhD, San Raffaele Scientific Institute

Title: Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to limit relapse after HCT
Speaker: Simone Minnie, PhD; Fred Hutchinson Cancer Center

11:45 – 12:30 Lunch

12:00-12:45 Pfizer Product Theater

13:00 – 13:45 Session III: Mechanism of Relapse – Auto
Chairs:
Anna Sureda, MD; Institut Català d’Oncologia-Hospital Duran i Reynals, ES
Marcos de Lima, MD, The Ohio State University, US

Title: Mechanisms of relapse after ASCT in multiple myeloma
Speaker: Niccolo Bolli, MD, PhD; Universita degli Studi di Milano Statale

Title: Lymphoma recurrence after autologous stem cell transplantation
Speaker: Lapo Alinari, MD, PhD; Ohio State University

13:45 – 14:15 Break
Session IV.A: Mechanism of Relapse – CAR Resistance

Chairs:
Nirali Shah, MD, MHSc, National Cancer Institute, US
Michael Bishop, MD; University of Chicago, US

Title: Determinants of resistance to anti-CD19 CAR T-cells in large B-cell lymphoma
Speaker: Brian Sworder, MD, PhD; Stanford Health Care

Title: Harnessing CAR/TCR cross-talk to enhance immunotherapeutic precision
Speaker: Naomi Taylor, MD, PhD; National Cancer Institute

Title: ALL relapse prevention with HCT following CD19 CAR T cell remission
Speaker: Corrine Summers, MD; Seattle Children’s Hospital/Fred Hutchinson Cancer Center

15:30 – 16:15
Keynote Lecture: Towards the Development of Synthetic Immunity to Cancer
Kole Roybal, PhD; University of California, San Francisco

16:15 – 17:15
Best Oral Abstracts

Abstract Title: Guided Lymphocyte Immunopeptide Derived Expansion (GLIDE) and Infusion, a Phase I clinical trial of anti-minor histocompatibility antigen expanded T cells to target leukemia relapsing after HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation
Abstract Presenter: Sylvie Lachance MD, FRCPC; Hôpital Maisonneuve-Rosemont

Abstract Title: Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk AML and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) post-hematopoietic cell transplant (HCT) maintenance
Abstract Presenter: Guenther Koehne, MD, PhD; Miami Cancer Institute

Abstract Title: Immune reconstitution in human bone marrow demonstrates unique features that may correlate with leukemia relapse risk post-transplant
Abstract Presenter: Susan Ehrenkranz De Wolf, MD; Memorial Sloan Kettering Cancer Center

Abstract Title: Mutation clearance of driver mutations after transplantation for myelofibrosis predicts outcome
Abstract Presenter: Nico Gagelmann, MD; University Medical Center Hamburg-Eppendorf

17:15 – 18:45
Welcome Reception

Saturday, 11 November 2023

07:00 – 08:00
Product Theater

08:00 – 08:45
Keynote Lecture: Missing the Major Correlate of Risk of Posttransplant Relapse
John DiPersio, MD, PhD; Washington University, St. Louis, US

08:45 – 09:30
Session V: Mechanism of Relapse – CAR Exhaustion
Chairs:
Robert Zeiser, MD; University of Freiburg, DE
Shannon McCurdy, MD; University of Pennsylvania, US

Title: How to improve the anti-tumor activity of T cells – metabolism gives some answers
Speaker: Petya Apostolova, MD; University of Basel, Switzerland

Title: Lessons from azithromycin after alloHSCT: how an antibiotic can promote relapse by disrupting immune and metabolic networks
Speaker: David Michonneau, MD, PhD; Hopital Saint-Louis

09:30 – 10:00
Break
10:00 – 11:15  Session VI: Minimal Residual Disease
Chairs: Charles Craddock, MD; University Hospitals of Birmingham, UK
        Brenda Sandmaier, MD; Fred Hutchinson Cancer Research Center, US
Title: MRD and Relapse after Transplant in Patients with AML
Speaker: Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath, University of Birmingham
Title: Using MRD to Predict and Prevent Relapse after HCT and CAR Therapy
Speaker: Michael Pulsipher, MD, University of Utah
Title: Assessment, considerations and management of Multiple myeloma patients following front line autologous stem cell transplantation
Speaker: Graham Jackson, MD, Newcastle University

11:15 – 12:30  Session VII: Relapse Prevention
Chairs: David Porter, MD; University of Pennsylvania, US
        Chiara Bonini, MD; San Raffaele Scientific Institute, IT
Title: Non-targeted strategies for relapse prevention
Speaker: Victoria Potter, BSc, MBBS; Kings Private Hospital
Title: FLT3 inhibitors as maintenance therapy after HCT
Speaker: Alexander Perl, MD; University of Pennsylvania
Title: Inhibition of MDM2 for relapse prevention
Speaker: Nana Talvard-Balland, PhD; University of Freiburg

12:30 – 13:45  Lunch & Product Theater
12:45-13:15  California Institute for Regenerative Medicine

13:45 – 15:15  Session VIII: Treatment of Relapse
Chairs: Rayne Rouce, MD; Texas Children's Hospital/Baylor College of Medicine, US
        Saar Gill, MD, PhD; University of Pennsylvania, US
        Bronwen Shaw, MD, PhD; CIBMTR/Medical College of Wisconsin, US
        Takanori Teshima, MD, PhD; Hokkaido University, JP
Title: Treatment of Relapse Post Allogeneic Stem Cell Transplantation: A Overview
Speaker: Saar Gill, MD, PhD; University of Pennsylvania
Title: How I treat AML relapse post allogeneic stem cell transplantation
Speaker: Leonido Luznik, MD; Johns Hopkins Medicine
Title: Treatment of Relapsed Myeloid Disease Post Allogeneic HCT: HMA, Venetoclax and DLI
Speaker: Hugo Fernandez, MD; Moffit Cancer Center
Title: 4 How I treat ALL relapse post allogeneic stem cell transplantation(including Ph+ and Ph-, and T-ALL)
Speaker: Rayne Rouce, MD; Texas Children's Hospital/Baylor College of Medicine

15:15 – 15:30  Concluding Remarks

*This agenda is current as of September 2023 but is subject to change.